|
74 Companies |
|
57 Products |
|
57 Products |
|
42 Mechanisms of Action |
|
2 Trials |
|
680 News |
|
| «12345678910111213...1314» |
- Trial completion: Efficacy and Safety of Silk Fibroin With Bioactive Coating Layer Dressing (clinicaltrials.gov) - Nov 3, 2016
P1/2, N=29, Completed, Sponsor: Chulalongkorn University
Recruiting --> Completed
- Enrollment change, Trial termination, Trial primary completion date: A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts (clinicaltrials.gov) - Nov 2, 2016
P4, N=50, Terminated, Sponsor: University of British Columbia
Recruiting --> Completed N=242 --> 50 | Not yet recruiting --> Terminated | Trial primary completion date: Dec 2012 --> Jan 2012; There was no clear benefit but numerous side effects.
- valacyclovir / Generic mfg.
Trial primary completion date: Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals? (clinicaltrials.gov) - Oct 31, 2016
P3, N=202, Active, not recruiting, Sponsor: University Health Network, Toronto
N=242 --> 50 | Not yet recruiting --> Terminated | Trial primary completion date: Dec 2012 --> Jan 2012; There was no clear benefit but numerous side effects. Trial primary completion date: Sep 2016 --> Mar 2017
- Trial completion: Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) (clinicaltrials.gov) - Oct 27, 2016
P=N/A, N=1927, Completed, Sponsor: University Hospital, Geneva
Trial primary completion date: Sep 2016 --> Mar 2017 Active, not recruiting --> Completed
- valacyclovir / Generic mfg.
Trial completion, Trial primary completion date: Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia (clinicaltrials.gov) - Oct 26, 2016
P4, N=134, Completed, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed Enrolling by invitation --> Completed | Trial primary completion date: May 2016 --> Sep 2016
- Trial primary completion date, IO biomarker: Interferon Responses in Eczema Herpeticum (clinicaltrials.gov) - Oct 21, 2016
P=N/A, N=84, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Enrolling by invitation --> Completed | Trial primary completion date: May 2016 --> Sep 2016 Trial primary completion date: Aug 2016 --> Jan 2016
- Trial primary completion date: Registry for the Atopic Dermatitis Research Network (clinicaltrials.gov) - Oct 19, 2016
P=N/A, N=2600, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Aug 2016 --> Jan 2016 Trial primary completion date: Dec 2016 --> Feb 2020
- Trial completion, Enrollment change, Trial primary completion date, IO biomarker: Interferon Responses in Eczema Herpeticum (clinicaltrials.gov) - Oct 19, 2016
P=N/A, N=84, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Dec 2016 --> Feb 2020 Recruiting --> Completed | N=120 --> 84 | Trial primary completion date: Dec 2016 --> Aug 2016
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: PIONEER (OLE): Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) - Sep 28, 2016
P3, N=510, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed | N=120 --> 84 | Trial primary completion date: Dec 2016 --> Aug 2016 Active, not recruiting --> Completed
- |||| Trial primary completion date: Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex Vaccine (clinicaltrials.gov) - Sep 21, 2016
P3, N=671, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Trial primary completion date: Jan 2006 --> Sep 2005
- Trial completion: A New Reagent Assay Examining Natural Parvovirus B19 Infection in Sickle Cell Disease (clinicaltrials.gov) - Sep 19, 2016
P=N/A, N=24, Completed, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Jan 2006 --> Sep 2005 Active, not recruiting --> Completed
- ||| Olorofim (orotomide) / F2G
Trial completion: F901318 Multiple Ascending Dose Study (clinicaltrials.gov) - Sep 19, 2016
P1, N=72, Completed, Sponsor: F2G Ltd.
Active, not recruiting --> Completed Recruiting --> Completed
- | OrienX010 / OrienGene
Trial completion, Trial primary completion date: A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer (clinicaltrials.gov) - Sep 1, 2016
P1, N=18, Completed, Sponsor: OrienGene Biotechnology Ltd.
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Oct 2013 --> May 2014
- Decadron (dexamethasone) / Merck (MSD)
Trial primary completion date: Use of Corticosteroids in Children With Cellulitis (clinicaltrials.gov) - Aug 31, 2016
P=N/A, N=124, Recruiting, Sponsor: Hospital General de Ni
Recruiting --> Completed | Trial primary completion date: Oct 2013 --> May 2014 Trial primary completion date: Jun 2016 --> Oct 2016
- | pentoxifylline / Generic mfg.
Trial completion, Enrollment change, IO biomarker, Immunomodulating: Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis (clinicaltrials.gov) - Aug 23, 2016
P2/3, N=75, Completed, Sponsor: Centro Internacional de Entrenamiento e Investigaciones M
Trial primary completion date: Jun 2016 --> Oct 2016 Recruiting --> Completed | N=100 --> 75
- Trial completion, Trial primary completion date: Pharmacokinetics of Miltefosine in Children and Adults (clinicaltrials.gov) - Aug 22, 2016
P4, N=60, Completed, Sponsor: Centro Internacional de Entrenamiento e Investigaciones Médicas
Recruiting --> Completed | N=100 --> 75 Recruiting --> Completed | Trial primary completion date: Dec 2014 --> May 2014
- Trial completion: Pulsed Dye Laser Treatment of Onychomycosis (clinicaltrials.gov) - Aug 19, 2016
P=N/A, N=11, Completed, Sponsor: Thomas Jefferson University
Recruiting --> Completed | Trial primary completion date: Dec 2014 --> May 2014 Recruiting --> Completed
- Kepivance (palifermin) / SOBI, Amgen
Trial termination: Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis (clinicaltrials.gov) - Aug 12, 2016
P1/2, N=1, Terminated, Sponsor: Brett King
Recruiting --> Completed Recruiting --> Terminated; Low enrollment numbers precluded completion of the study during a reasonable amount of time.
- | gentamicin sulfate / Generic mfg.
Trial completion: Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama (clinicaltrials.gov) - Aug 11, 2016
P3, N=400, Completed, Sponsor: U.S. Army Medical Research and Materiel Command
Recruiting --> Terminated; Low enrollment numbers precluded completion of the study during a reasonable amount of time. Active, not recruiting --> Completed
- || Olorofim (orotomide) / F2G
Trial primary completion date: F901318 Multiple Ascending Dose Study (clinicaltrials.gov) - Aug 9, 2016
P1, N=72, Recruiting, Sponsor: F2G Ltd.
Active, not recruiting --> Completed Trial primary completion date: Feb 2016 --> Sep 2016
- | HSV vaccine (GEN-003) / Genocea, Shionogi
Trial completion: Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study (clinicaltrials.gov) - Jul 29, 2016
P2, N=37, Completed, Sponsor: Genocea Biosciences, Inc.
Trial primary completion date: Feb 2016 --> Sep 2016 Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia (clinicaltrials.gov) - Jul 26, 2016
P1/2, N=80, Completed, Sponsor: Drugs for Neglected Diseases
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Nov 2015 --> May 2016
- ||| Enrollment change: A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts (clinicaltrials.gov) - Jul 19, 2016
P1/2, N=54, Completed, Sponsor: Nowarta Biopharma Inc
Active, not recruiting --> Completed | Trial primary completion date: Nov 2015 --> May 2016 N=78 --> 54
- |||| VCL-HB01 / Brickell
Trial completion: Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults (clinicaltrials.gov) - Jul 16, 2016
P1/2, N=165, Completed, Sponsor: Vical
N=78 --> 54 Active, not recruiting --> Completed
- Tembexa (brincidofovir oral) / SymBio Pharma
Enrollment change, Trial withdrawal: A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease) (clinicaltrials.gov) - Jun 10, 2016
P1/2, N=0, Withdrawn, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed N=32 --> 0 | Not yet recruiting --> Withdrawn
- Zeven (dalbavancin) / RaQualia, AbbVie
Phase classification: Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Jun 2, 2016
P3b, N=698, Completed, Sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc
N=32 --> 0 | Not yet recruiting --> Withdrawn Phase classification: P3 --> P3b
- || Trial primary completion date: Evaluation of the HSV 1 & 2 Assay in Specimens From Symptomatic Subjects (clinicaltrials.gov) - May 14, 2016
P=N/A, N=839, Active, not recruiting, Sponsor: Hologic, Inc.
Phase classification: P3 --> P3b Trial primary completion date: Apr 2016 --> Aug 2016
- | valacyclovir / Generic mfg.
Trial completion, Trial primary completion date: VALIANT Pilot: Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2? (clinicaltrials.gov) - May 13, 2016
P3, N=60, Completed, Sponsor: University Health Network, Toronto
Trial primary completion date: Apr 2016 --> Aug 2016 Recruiting --> Completed | Trial primary completion date: Jun 2011 --> Aug 2013
- ||| Trial completion, HEOR: The Psychosocial and Economic Burden of Genital Warts (clinicaltrials.gov) - May 10, 2016
P=N/A, N=224, Completed, Sponsor: BEMFAM-Bem Estar Familiar
Recruiting --> Completed | Trial primary completion date: Jun 2011 --> Aug 2013 Not yet recruiting --> Completed
- mupirocin / Generic mfg.
Trial primary completion date: HOME2DS: Individualized vs. Household MRSA Decolonization (clinicaltrials.gov) - May 3, 2016
P=N/A, N=600, Enrolling by invitation, Sponsor: Washington University School of Medicine
Not yet recruiting --> Completed Trial primary completion date: Jun 2016 --> Jan 2017
- Enrollment closed, Enrollment change, Trial primary completion date: A New Reagent Assay Examining Natural Parvovirus B19 Infection in Sickle Cell Disease (clinicaltrials.gov) - May 3, 2016
P=N/A, N=24, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Jun 2016 --> Jan 2017 Recruiting --> Active, not recruiting | N=89 --> 24 | Trial primary completion date: Oct 2016 --> Mar 2016
- |||| Enrollment open, Trial initiation date: A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum (clinicaltrials.gov) - Apr 26, 2016
P2, N=60, Recruiting, Sponsor: ViroXis Corporation
Recruiting --> Active, not recruiting | N=89 --> 24 | Trial primary completion date: Oct 2016 --> Mar 2016 Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Feb 2016
- | gentamicin sulfate / Generic mfg.
Enrollment closed: Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama (clinicaltrials.gov) - Apr 21, 2016
P3, N=400, Active, not recruiting, Sponsor: U.S. Army Medical Research and Materiel Command
Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Feb 2016 Recruiting --> Active, not recruiting
- | Trial completion: Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe Nail (clinicaltrials.gov) - Apr 21, 2016
P2, N=48, Completed, Sponsor: Taro Pharmaceuticals USA
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- acyclovir / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date: Antiviral Prophylaxis in a Burn Population (clinicaltrials.gov) - Apr 21, 2016
P2/3, N=0, Withdrawn, Sponsor: Southern Illinois University
Active, not recruiting --> Completed N=250 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2018 --> Apr 2016
- Trial primary completion date: Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis (clinicaltrials.gov) - Apr 19, 2016
P3, N=264, Active, not recruiting, Sponsor: Oswaldo Cruz Foundation
N=250 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2018 --> Apr 2016 Trial primary completion date: Dec 2015 --> Apr 2016
- || Enrollment closed, Enrollment change: Evaluation of the HSV 1 & 2 Assay in Specimens From Symptomatic Subjects (clinicaltrials.gov) - Apr 18, 2016
P=N/A, N=839, Active, not recruiting, Sponsor: Hologic, Inc.
Trial primary completion date: Dec 2015 --> Apr 2016 Recruiting --> Active, not recruiting | N=1900 --> 839
- | Trial completion, Trial primary completion date: A Double-Blind, Randomized, Placebo-Controlled Study of Topical VDO for the Treatment of Herpes Simplex Labialis (clinicaltrials.gov) - Apr 15, 2016
P2, N=40, Completed, Sponsor: Yung Shin Pharm. Ind. Co., Ltd.
Recruiting --> Active, not recruiting | N=1900 --> 839 Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Dec 2015
- || Ilaris (canakinumab) / Novartis
Trial completion: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease (clinicaltrials.gov) - Apr 14, 2016
P3, N=17, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Dec 2015 Recruiting --> Completed
- Trial primary completion date: Registry for the Atopic Dermatitis Research Network (clinicaltrials.gov) - Apr 12, 2016
P=N/A, N=2600, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Trial primary completion date: Mar 2016 --> Dec 2016
- Trial primary completion date, IO biomarker: Interferon Responses in Eczema Herpeticum (clinicaltrials.gov) - Apr 12, 2016
P=N/A, N=120, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Mar 2016 --> Dec 2016 Trial primary completion date: Mar 2016 --> Dec 2016
- |||| Trial completion, Enrollment change: A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts (clinicaltrials.gov) - Apr 4, 2016
P1/2, N=78, Completed, Sponsor: Nowarta Biopharma Inc
Trial primary completion date: Mar 2016 --> Dec 2016 Not yet recruiting --> Completed | N=120 --> 78
- aztreonam / Generic mfg., vancomycin / Generic mfg., ceftaroline fosamil / Generic mfg.
Enrollment change: Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections. (clinicaltrials.gov) - Mar 31, 2016
P3, N=4, Terminated, Sponsor: AstraZeneca
Not yet recruiting --> Completed | N=120 --> 78 N=60 --> 4
- doxycycline / Generic mfg.
Trial completion, Trial primary completion date: Doxycycline in Therapy of Erythema Migrans (clinicaltrials.gov) - Mar 25, 2016
P=N/A, N=400, Completed, Sponsor: University Medical Centre Ljubljana
N=60 --> 4 Recruiting --> Completed | Trial primary completion date: May 2013 --> Oct 2014
- | Trial completion, Trial primary completion date: Pilot Study to Evaluate Plasma Treatment of Onychomycosis (clinicaltrials.gov) - Mar 24, 2016
P=N/A, N=15, Completed, Sponsor: Moe Medical Devices
Recruiting --> Completed | Trial primary completion date: May 2013 --> Oct 2014 Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Mar 2015
- amphotericin b liposome / Generic mfg.
Trial primary completion date, Combination therapy, Monotherapy: Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. (clinicaltrials.gov) - Mar 21, 2016
P3, N=132, Active, not recruiting, Sponsor: Drugs for Neglected Diseases
Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Mar 2015 Trial primary completion date: Jan 2016 --> Aug 2016
- Enrollment closed, Trial primary completion date: LASER-1: Laser Therapy for Onychomycosis in Patients Wih Diabetes at Risk for Diabetic Foot Complications (clinicaltrials.gov) - Mar 21, 2016
P=N/A, N=64, Active, not recruiting, Sponsor: Medical Research Foundation, The Netherlands
Trial primary completion date: Jan 2016 --> Aug 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Mar 2017
- ||||||| Amenalief (amenamevir) / Maruho
Trial completion: Phase III Study of ASP2151 in Herpes Simplex Patients (clinicaltrials.gov) - Mar 17, 2016
P3, N=453, Completed, Sponsor: Maruho Co., Ltd.
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Mar 2017 Active, not recruiting --> Completed
- ||||||| Amenalief (amenamevir) / Maruho
Trial completion: Open-label Study of ASP2151 in Herpes Simplex Patients (clinicaltrials.gov) - Mar 16, 2016
P3, N=250, Completed, Sponsor: Maruho Co., Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| HSV vaccine (GEN-003) / Genocea, Shionogi
Trial completion: Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine (clinicaltrials.gov) - Mar 8, 2016
P2, N=310, Completed, Sponsor: Genocea Biosciences, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed